Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01639716

Enrollment

Registered

2012-07-13

Start date

2011-05-31

Completion date

2012-06-30

Last updated

2012-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

Survey, interleukin status

Brief summary

The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* newly diagnosed non hodgkin lymphoma * Diffuse large B cell lymphoma and T cell lymphoma patients

Exclusion criteria

* under 18 age * parasitosis * allergic status

Design outcomes

Primary

Measure	Time frame	Description
Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma	This study ended within 13 months	We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels.

Secondary

Measure	Time frame	Description
survey as months	During study which was 13 months	Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months.

Countries

Turkey (Türkiye)

Outcome results